Pulmonx reports 6 percent revenue growth: meaning for Pulmonx stock

Published on 10/28/2026 at 05:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue reached USD 22.84 million, up 6.00 percent year over year. For Pulmonx stock, net loss narrowed to USD 8.39 million.

Revenue returns to growth

Pulmonx reported USD 22.84 million in third-quarter revenue on October 27, 2026.
Gross margin reached 76.00 percent in the third quarter of 2026.
Pulmonx stock was last at USD 1.98 on October 27, 2026 at 4:00 p.m. EDT on the Nasdaq.
Full-year 2026 revenue guidance remained USD 90 million to USD 92 million.

PULM, US7458481014, Illustration mit AI erstellt.

Pulmonx Corporation (ISIN US7458481014) reported third-quarter revenue of USD 22.84 million, up 6.00 percent from the same period in 2025. The results dated October 27, 2026 showed a narrower loss and renewed growth in the companys core business.

What the revenue return means

According to Yahoo Finance, worldwide revenue increased from USD 21.50 million in the third quarter of 2025 to USD 22.84 million in the third quarter of 2026. U.S. revenue rose 7.00 percent to USD 14.91 million, while international revenue increased 5.00 percent to USD 7.92 million.

The operating picture also improved. Gross margin rose to 76.00 percent from 75.00 percent year over year, and operating expenses fell 18.00 percent to USD 24.89 million. GAAP net loss narrowed to USD 8.39 million, or USD 0.19 per share, from USD 13.96 million, or USD 0.34 per share, in the prior-year quarter, while adjusted EBITDA loss declined to USD 3.53 million from USD 8.22 million, according to Yahoo Finance.

Three dated milestones

On August 25, 2026, Weiss Ratings changed its rating from sell e+ to sell d-, as reported by MarketBeat. On October 13, 2026, Pulmonx announced that it would publish third-quarter results on October 27, 2026, according to GlobeNewswire. On October 27, 2026, the company reported USD 22.84 million in quarterly revenue and reiterated its full-year outlook.

Guidance keeps cash in view

Pulmonx maintained full-year 2026 revenue guidance of USD 90 million to USD 92 million and expects full-year gross margin of 77.00 percent. The company also projects operating expenses of USD 108 million to USD 109 million and a USD 22 million reduction in cash, cash equivalents and marketable securities during 2026.

Nasdaq price and company value

The Nasdaq value was last at USD 1.98 on October 27, 2026 at 4:00 p.m. EDT. Pulmonx had a market capitalization of USD 85.0 million and a 52-week range of USD 1.13 to USD 2.89, with both market figures dated October 27, 2026.